血清趋化因子对HBeAg阳性慢性乙型肝炎患者经聚乙二醇干扰素α治疗后持续病毒学应答的影响

李彦; 王霞; 成立伟; 潘修成; 单奔; 耿建; 刘瑞霞; 傅涓涓; 李丽

doi:10.3969/j.issn.1001-5256.2016.03.013

血清趋化因子对HBeAg阳性慢性乙型肝炎患者经聚乙二醇干扰素α治疗后持续病毒学应答的影响

DOI: 10.3969/j.issn.1001-5256.2016.03.013

徐州医学院附属医院感染病科

基金项目:

江苏省临床科技专项(BL2012043)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2101
- HTML全文浏览量: 34
- PDF下载量: 350
- 被引次数: 0
出版历程
- 收稿日期: 2015-08-31
- 出版日期: 2016-03-20

Effects of serum levels of chemokines on sustained virological response in patients with HBeAg-positive chronic hep-atitis B after treatment with pegylated interferon α-2b

Department of Infectious Diseases,Affiliated Hospital of Xuzhou Medical College

Research funding:

摘要

摘要: 目的研究HBe Ag阳性慢性乙型肝炎患者聚乙二醇干扰素（PEG-IFN）治疗过程中血清γ-干扰素诱导蛋白-10（IP-10）、γ-干扰素诱导单核因子（Mig）及调节激活正常T淋巴细胞表达和分泌因子（RANTES）水平变化特点及其对PEG-IFN疗效的预测价值。方法收集2012年2月-2013年12月于徐州医学院附属医院接受PEG-IFNα-2b治疗的HBe Ag阳性CHB患者53例,其中46例完成48周治疗后继续随访24周,根据有无出现持续病毒学应答（SVR）分为A组（出现SVR,n=17）和B组（未出现SVR,n=29）。测定患者基线,治疗12、24、48周及治疗后24周外周静脉血清IP-10、Mig、RANTES、HBV DNA、HBs Ag及ALT水平。计量资料两组间比较采用t检验,组内两两比较采用配对t检验,相关性采用Pearson相关系数分析。计数资料组间比较采用χ2检验。结果患者基线血清IP-10、Mig水平A组显著高于B组,HBs Ag水平A组则低于B组,差异均有统计学意义（t值分别为2.696、2.963、2.401,P值均<0.05）。患者基线IP-10、Mig...
- 肝炎,乙型,慢性 /
- 炎症趋化因子类 /
- 干扰素α
Abstract: Objective To investigate the changes in serum levels of interferon( IFN)- γ- inducible protein 10( IP- 10),monokine induced by IFN- γ( Mig),and chemokine regulated upon activation,normal T cell expressed and secreted( RANTES) in patients with HBe Ag- positive chronic hepatitis B( CHB) undergoing pegylated interferon( PEG- IFN) therapy,and to explore their predictive values for the efficacy of PEG- IFN therapy. Methods Fifty- three patients with HBe Ag- positive CHB who received PEG- IFN α- 2b therapy in our hospital from February 2012 to December 2013 were enrolled as subjects. Forty- six out of the fifty- three patients were followed up for 24 weeks after 48 weeks of treatment. According to the incidence of sustained virological response( SVR),these patients were divided into A group( SVR,n = 17) and B group( NO SVR,n = 29). Serum levels of IP- 10,Mig,RANTES,hepatitis B virus( HBV) DNA,HBs Ag,and alanine aminotransferase( ALT) in peripheral venous blood were measured at baseline,after 12,24,and 48 weeks of treatment,and at 24 weeks after treatment. Comparison of continuous data between two groups and within the groups was made by t test and paired t test,respectively. Correlation was analyzed using the Pearson correlation coefficient. Between- group comparison of categorical data was made by χ2test. Results Compared with the B group,the A group had significantly higher baseline serum levels of IP- 10 and Mig and a significantly lower level of HBs Ag( t = 2. 696,P < 0. 05; t = 2. 963,P < 0. 05; t = 2. 401,P < 0. 05). The baseline levels of IP- 10 and Mig were positively correlated with the baseline level of ALT( r = 0. 570,P < 0. 05; r = 0. 317,P < 0. 05). Compared with the baseline levels,patients had significantly reduced serum levels of HBV DNA,HBs Ag,ALT,and Mig after 12 weeks of treatment( t = 2. 126,P <0. 05; t = 2. 217,P < 0. 05; t = 2. 376,P < 0. 05; t = 2. 776,P < 0. 05) and 24 weeks of treatment( t = 2. 635,P < 0. 05; t = 2. 453,P <0. 05; t = 2. 627,P < 0. 05; t = 2. 803,P < 0. 05). There were significant differences in levels of IP- 10 and Mig between the SVR group and non- SVR group before and after 12 and 24 weeks of treatment( all P < 0. 05). In the A group,the levels of Mig after 12 and 24 weeks of treatment were significantly lower than the baseline level( t = 3. 061,P < 0. 01; t = 3. 105,P < 0. 01). In the B group,the serum level of Mig after 24 weeks of treatment was significantly lower than the baseline level( t = 2. 632,P < 0. 01). The baseline serum levels of IP-10,Mig,and HBs Ag had predictive values for SVR( all P < 0. 05). In the 46 patients,the incidence of SVR in patients with baseline levels of Mig higher than 80 pg / ml( 12 /20) was significantly higher than that in patients with baseline levels of Mig lower than 80 pg / ml( 5 /26)( 60. 0% vs 19. 2%,χ2= 8. 06,P < 0. 01); the incidence of SVR in patients with baseline levels of IP- 10 higher than 120 pg / ml( 12 /25) was significantly higher than that in patients with baseline levels of IP- 10 lower than 120 pg/ml( 5 /21)( 48. 0% vs 23. 8%,χ2= 3. 86,P < 0. 05). Conclusion The baseline serum levels of IP- 10 and Mig are both predictors of the incidence of SVR in patients with HBe Ag- positive CHB undergoing PEG- IFN therapy,and Mig provides superior prediction.
- hepatitis B,chronic /
- chemokines /
- inferon-alpha

HTML全文

参考文献(16)

[1]LAING KJ,SECDMBES CJ.Chemokines[J].Dev Comp Immunol,2004,28(5):443-460.

[2]FJUIIE S,HIESHIMA K,LZAWA D,et al.Proinflammatory cytokines induce liver and activation-regulaled chemokine/macrophage inflammatory protein-3alpha/CCL20 in mucosal epithelial cells through NF-kappa B[J].Int Immunol,2001,13(10):1255-1263.

[3]TREBST C,STAUGAITIS SM,TUCKY B,et al.Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system(CNS)[J].Neuropathol Appl Neurobiol,2003,29(6):584-595.

[4]QIAO B,SUN XH,ZHANG X,et al.Research advances in the role of CCR5 in chronic hepatitis B[J].Chin J Immunol,2015,31(9):1269-1273.(in Chinese)乔兵,孙学华,张鑫,等.CCR5在慢性乙型肝炎中的研究进展[J].中国免疫学杂志,2015,31(9):1269-1273.

[5]TAN AT,KOH S,GOH W,et al.A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B[J].J Hepatol,2010,52(3):330-339.

[6]WANG Y,ZHAO C,ZHANG L,et al.Predictive value of interferon-gamma inducible protein 10 k D for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients[J].Antiviral Res,2014,103(3):51-59.

[7]LEE IC,HUANG YH,SU CW,et al.CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy:a pilot study[J].PLo S One,2013,8(10):e76798.

[8]SONNEVELD MJ,ARENDS P,BOONSTRA A,et al.Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBe Ag-positive chronic hepatitis B[J].J Hepatol,2013,58(5):898-903.

[9]Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[10]CHEN SH,WU HL,KAO JH,et al.Persistent hepatitis B viral replication in a FVB/N mouse model:impact of host and viral factors[J].PLo S One,2012,7(5):e36984.

[11]GROOM JR,LUSTER AD.CXCR3 in T cell function[J].Exp Cell Res,2011,317(5):620-631.

[12]GROOM JR,LUSTER AD.CXCR3 ligands:redundant,collaborative and antagonistic functions[J].Immunol Cell Biol,2011,89(2):207-215.

[13]APPAY V,BROWN A,CFIBBES S,et al.Aggregation of RANTES is responsible for inflammatory properties Characterization of non-aggregating,non-inflammatory RANTES mutants[J].J Biol Chem,1999,274(39):27505-27512.

[14]WANG YD,ZHANG L,SHEN C,et al.Expression of interferongamma inducible protein-10 and its receptor in various type of hepatitis B[J].Chin J Infect Dis,2014,32(1):43-47.(in Chinese)王亚东,张莉,申川,等.慢性乙型肝炎病毒感染者不同阶段γ干扰素及其诱导蛋白10表达变化[J].中华传染病杂志,2014,32(1):43-47.

[15]DUAN ZP,ZHAO XY,HUANG DZ,et al.RANTES gene single nucleotide polymorphisms and expression in patients with chronic hepatitis B virus infection[J].Chin Med J(Engl),2005,118(11):909-914.

[16]MARRA F,TACKE F.Roles for chemokines in liver disease[J].Gastroenterology,2014,147(3):577-594.

施引文献

资源附件(0)

访问统计